Loading...
XSHE002004
Market cap1.15bUSD
Jan 14, Last price  
4.33CNY
1D
1.41%
1Q
-2.70%
Jan 2017
-52.26%
Name

Huapont Life Sciences Co Ltd

Chart & Performance

D1W1MN
XSHE:002004 chart
P/E
27.95
P/S
0.73
EPS
0.15
Div Yield, %
8.96%
Shrs. gr., 5y
-0.46%
Rev. gr., 5y
1.86%
Revenues
11.59b
-12.38%
272,531,695273,504,759285,226,933492,372,337575,720,357544,520,701541,224,471638,097,6923,877,392,8154,463,630,6414,866,688,8026,174,305,6987,092,779,9749,108,900,35810,573,627,54110,091,370,48610,876,361,87312,359,182,98813,232,365,56711,594,590,416
Net income
302m
-73.19%
47,648,38952,499,38758,445,973206,455,18388,810,031127,684,400132,041,719305,278,505332,384,323302,449,093429,183,616636,625,439566,868,339507,905,574822,817,465931,903,068895,005,575924,961,2861,126,736,284302,122,026
CFO
1.59b
-33.99%
70,600,49543,692,33866,102,53079,208,796113,757,667123,526,89679,837,753135,225,574257,750,433349,505,047455,964,027342,447,446511,900,516591,399,5071,908,623,1262,082,144,7172,372,722,4381,269,621,9852,407,855,3431,589,476,654
Dividend
Jun 03, 20240.22 CNY/sh
Earnings
May 23, 2025

Profile

Huapont Life Sciences Co., Ltd. engages in the pharmaceutical and agrochemical businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and intermediates. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and ophthalmology, as well as health management products. In addition, the company provides pesticide technical, intermediate and preparation products, and GLP registration technical services. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co., Ltd. in September 2015. Huapont Life Sciences Co., Ltd. was founded in 2001 and is based in Chongqing, China. Huapont Life Sciences Co., Ltd. was formerly a subsidiary of Huipont Tourism Co. Ltd.
URL
http://www.huapont.com.cn/
IPO date
Jun 25, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,594,590
-12.38%
13,232,366
7.07%
Cost of revenue
9,362,928
10,302,379
Unusual Expense (Income)
NOPBT
2,231,662
2,929,987
NOPBT Margin
19.25%
22.14%
Operating Taxes
215,456
495,959
Tax Rate
9.65%
16.93%
NOPAT
2,016,206
2,434,027
Net income
302,122
-73.19%
1,126,736
21.81%
Dividends
(756,275)
(435,582)
Dividend yield
8.20%
4.31%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,681,140
6,263,999
Long-term debt
2,974,390
1,825,643
Deferred revenue
271,233
278,214
Other long-term liabilities
199,265
194,626
Net debt
791,795
962,692
Cash flow
Cash from operating activities
1,589,477
2,407,855
CAPEX
(1,284,122)
Cash from investing activities
(1,749,716)
Cash from financing activities
14,706
FCF
1,721,507
1,558,252
Balance
Cash
5,610,253
4,892,909
Long term investments
2,253,482
2,234,040
Excess cash
7,284,005
6,465,331
Stockholders' equity
10,796,257
11,773,814
Invested Capital
18,379,135
18,292,882
ROIC
11.00%
13.30%
ROCE
8.66%
11.78%
EV
Common stock shares outstanding
1,979,919
1,979,919
Price
4.66
-8.63%
5.10
-29.56%
Market cap
9,226,423
-8.63%
10,097,588
-29.56%
EV
16,497,775
17,419,108
EBITDA
3,210,340
3,730,216
EV/EBITDA
5.14
4.67
Interest
343,700
434,012
Interest/NOPBT
15.40%
14.81%